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ABBREVIATIONS 
%    : Percentage 
nm   : Nanometer 
v/v   : Volume by volume 
Min   : Minute 
mg   : Milligram 
µg   : Microgram 
ng   : Nanogram 
LC   : Liquid chromatography 
HPLC   : High-performance liquid chromatography 
GC   : Gas chromatography 
UV   : Ultraviolet 
 HPTLC             : High-performance thin layer chromatography 
TLC   : Thin layer chromatography 
LC-MS                        : Liquid chromatography-Mass spectroscopy 
mm   : Millimeter 
RSD   : Relative standard deviation 
µ mol   : Micromole 
RP-HPLC             : Reversed-phase high-performance liquid chromatography 
RI   : Refractive index 
USP   : United States Pharmacopoeia 
HETP   : Height equivalent to theoretical plate 
LOD   : Limit of detection 
LOQ   : Limit of quantification  
CV   : Coefficient of variance 
S/N   : Signal to noise ratio 
PDA                 : Photo diode array detector 
USFDA                       : United state Food and Drug Administration 
ODS                  : Octa decyl silane 
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INTRODUCTION 
 
GENERAL INTRODUCTION: 
             Analytical chemistry is a branch of chemistry that determines the nature and 
identity of a substance and its composition. In the early twentieth century there were 
only four accepted branches of chemistry, organic chemistry, inorganic chemistry, 
physical chemistry, biochemistry. At that time, analysis was considered to be a 
service to the other four branches. Its importance grew and in the process, absorbed 
techniques and skills from all other four branches. So by the 1950’s, analytical 
chemistry was finally accepted as a branch of chemistry in its own right. There are 
basically two types of analysis, qualitative analysis and quantitative analysis. The 
former identifies the nature of substance and if it is mixture, the nature of the 
components present, where as the latter determines the elemental composition of the 
substance and/ or the quantitative distribution of each component. 
Pharmaceutical analysis deals with the analysis of a pharmaceutical(s) 
substance. It is generally known that pharmaceutical is a chemical entity of 
therapeutic interest. A more appropriate term for pharmaceutical is active 
pharmaceutical ingredient (API) or active ingredient. 
Pharmaceutical analysts  in research and development(R&D) of Pharma 
industry plays a very comprehensive role in new drug development and follow up 
activities to assure that, a new drug product meets the established standards, its 
stability and continued to meet the purported quality throughout its shelf-life. 
The different activity of R&D includes drug development (synthesis and 
manufacture) formulation, clinical trials, evaluation and finally launching i.e. finished 
products. Closely associated with these processes are regulatory and quality assurance 
functions. 
Before submitting the drug product for approval to the regulatory authorities, 
assuring that all batches of drug products comply with specific standards, utilization 
of approved ingredients and production methods. It becomes the responsibility of 
pharmaceutical analysts in quality control (QC), quality assurance (QA) department. 
The methods are generally developed in an analytical R&D and transferred to QC or 
other department. 
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         Quality Assurance and Quality Control plays a central role in determining the 
safety and efficacy of medicines. A highly specific and sensitive analytical technique 
holds the key to design, development, standardization and quality control of medicinal 
products.1,2 
Modern pharmaceutical analysis entails much more than the analysis of active 
pharmaceutical ingredients or the formulated product. There are physicochemical 
properties of pharmaceutical compounds through the use of advanced instrumental 
methods. There is a need for quality assurance of pharmaceutical products throughout 
their shelf life. This requires that interactions of the drug substances with the 
excipients in the presence of residual solvents, as well as other potential degradation 
reactions that may occur in the formulated product. 
The pharmaceutical industry is under increased scrutiny from the government 
and public interest groups to contain costs and yet consistently deliver to market safe, 
efficacious products that fulfill unmet medical needs. The industry has streamlined its 
operations with respect to drug discovery, development and manufacturing. 
Traditionally viewed as a service organization, the analytical department has 
become a significant partner in the drug development process. Analytical data has 
become a critical path activity for the selection of candidate molecules for full 
development. Working under sample-limited conditions and in full compliances of 
current good manufacturing practice (cGMP), Pharmaceutical analysts are called on 
to generate accurate and precise data – almost on demand. 
Novel delivery systems pose special analytical challenges. The commonly 
used tests of pharmaceutical analysis generally entail compendial testing; these 
methods, method development, setting specifications, and method validation. The 
drug product remains with in specifications established to ensure its identity, strength, 
quality and purity. It is necessary to conduct stability studies to predict, evaluate and 
ensure drug product safety1. 
Analytical data are the foundation and backbone for pharmaceutical 
development, leading to approval and production of new drugs for market. Potential 
areas in pharmaceutical analysis are highlighted, based on the successful 
demonstration made with analysis of proteins, peptides, DNA, and small molecules 
including chiral separations. 
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MODERN PHARMACEUTICAL ANALYSIS: 
The activities that are highlighted are  
• Discovery of NCE and high- throughput screening. 
• Solid-state analysis of drug substances. 
• Degradation and impurity analysis of drug substances. 
• Preformulation analysis. 
• Analysis of solid oral dosage forms. 
• Analysis of injectable dosage forms. 
• Compendial testing. 
• Method development. 
• Setting specifications. 
• Method validation. 
• Stability studies. 
• Analytical methodology transfer. 
• Documentation and inspections. 
• Innovative analytical platforms. 
THE ANALYTICAL LITERATURE: 
            Selection of optimum conditions, possible interferences, sensitivity and 
selectivity, accuracy and precision are all factors pertinent to the performance of an 
assay that should be known to the analyst before experimental operations are begun. 
Vast amounts of information are available in the literature, and the skilled analyst will 
learn to find it and profit by it3.    
The discipline involves qualitative analysis and quantitative analysis. 
QUALITATIVE ANALYSIS: deals with identification of the substance4. 
QUANTITATIVE ANALYSIS: deals with the determination of how much of the 
constituent are present4. 
          The applied science of analytical chemistry is instrumental analysis, which 
involves the study of theoretical principle of various instrumental methods. 
In this the physical property of a substance is measured to determine its chemical 
composition. These methods save the time and avoid chemical separation and give 
increased accurate results. 
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They are equally important in pharmacokinetics and drug metabolism studies 
both of which are fundamental to the assessment of bioavailability and the duration of 
clinical response.  
The pharmaceutical analysts play a major role in assuring the identity, safety, 
efficacy and quality of drug product. Safety and efficacy studies require that drug 
substance and drug product meet two critical requirement. 
¾ Established identity and purity 
¾ Established bioavailability and dissolution 
           Until 1920 all the methods were based upon volume and mass like volumetric 
and gravimetric methods have come to be known as classical or chemical method of 
analysis. 
        After that there is a drastic change in the field of pharmaceutical analysis due to 
the introduction of highly sensitive instrumental methods. In instrumental methods a 
physical property of a substance is measured to determine its chemical composition. 
These methods may be used by the analytical chemist to save time with increased 
accuracy in the method. The following are the important instrumental techniques 
used5,6,7. 
A. Electroanalytical Methods: These methods involve the measurement of 
current, voltage or resistance in relation to the concentration of a certain 
species in solution. Techniques are : 
(i) Coulomety 
(ii) Voltametry 
(iii) Potentiometry 
(iv) Conductimetry 
B. Spectroscopic Methods:Spectroscopic methods of analysis depend on: 
Measurement of the amount of radiant energy of a particular wavelength 
absorbed or emitted by the sample. 
(i) Absorption Methods 
• Atomic absorption spectroscopy (AAS) 
(ii) Emission Methods 
• Flame Photometry 
• Emission Spectroscopy 
• Fluorimetry 
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(iii) Magnetic Resonance Spectroscopy 
• Electron spin resonance (ESR) spectroscopy 
(iv) Photoelectron Spectroscopy (PES) 
(v) Scattering Methods 
C. Chromatographic and Electrophoretic Methods: These are essentially 
separative processes for mixtures of substances but equipped with modern 
detector systems, they are also adapted to identify components of mixtures. 
 
CHROMATOGRAPHY 
Russian botanist Michael Tswett invented chromatography as a separation 
technique.  He described in detail the separation of pigments, the colored substances 
by percolation through the column, followed by development with pure solvents.  The 
first paper of Tswett, was published in 1903, contains a study of more than 100 
absorbents used in conjunction with several different solvents.  
Types of Chromatography 
Chromatography characterized as a separation method based on the 
differential migration of solute through a system of two phases, one is mobile phase 
another one is stationary phase.  Chromatography is a technique by which the 
components in a sample, carried by the liquid or gaseous phase, are resolved by 
sorption, desorption steps on the stationary phase.  
Chromatography is mainly divided into two categories:  
1. Adsorption Chromatography8:  
Separation is mainly due to the interaction between solute and surface on the 
adsorbent.  In this, stationary phase is solid and mobile phase is liquid.  
e.g: TLC and HPTLC 
 
2. Partition Chromatography:  
Separation is based on the partition between two phases.  In this mode, both 
stationary phase and mobile phase are liquids  
e.g: HPLC, GLC, and PC. 
INTRODUCTION 
 
Dept of Pharmaceutical Analysis  Page 6 
 
TABLE-1 
 
DIFFERENT CHROMOTOGRAPHIC METHODS 
 
 
A) High performance liquid chromatography (HPLC) 
  It is analytical chromatographic technique that is useful for separation of ions 
or molecules that are dissolved in a solvent. 
TYPES OF HPLC: 
a) Normal phase chromatography9 
Normal phase chromatography is chromatographic technique that uses organic 
solvents for mobile phase and a polar stationary phase.  Here, the less polar compound 
elutes faster than the more polar compound. 
b) Reverse phase chromatography 
 Reverse phase chromatography - a bonded phase chromatography 
technique, uses water as base solvent.  Separation is based on solvent strength and 
selectivity.  Separation is also affected by column temperature and pH.  In general, the 
more polar compounds elute faster than the less polar compounds. UV detection is the 
most common detection technique used. 
 
 
Name Mechanism Stationary phase Mobile phase 
 
Paper 
chromatography 
Partition Liquid Liquid 
 
Thin layer 
Chromatography 
Adsorption Solid Liquid 
 
Gas 
Chromatography 
Adsorption/ Partition Liquid/ Solid Gas 
 
Column 
Chromatography 
Adsorption/ Partition Liquid/ Solid Liquid 
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MECHANISM: 
 The separation mechanism in reverse phase chromatography depends on the 
hydrophobic binding interaction between the solute molecule in the mobile phase and 
the immobilized hydrophobic ligand, i.e. the stationary phase. Reverse phase 
chromatography is an adsorptive process by experimental design, which relies on a 
partitioning mechanism to effect separation. The solute molecules partition (i.e. an 
equilibrium is established) between the mobile phase and the stationary phase. 
Stationary phase: 
 The most popular column is a octadecyl carbon chain (C18) bonded silica. 
This is followed by C8 bonded silica, pure silica, cyano bonded silica and phenyl 
bonded silica. C18, C8 and phenyl are dedicated reversed phase packing while cyano 
columns can be used in a reverse phase mode depending on analyte and mobile phase 
conditions. 
Mobile phase: 
 Mixture of water or aqueous buffers and organic solvents are used to elute 
analytes from a reversed phase column. The solvent have to be miscible with water 
and the most common organic solvents used are acetonitrile, methanol or 
tetrahydrofuran (THF). Other solvents can be used such as ethanol, 2-propanol 
(isopropyl alcohol). Elution can be performed isocratic (the water-solvent 
composition does not change during the separation process) or by using a gradient 
(the water-solvent composition does change during the separation process). The pH of 
the mobile phase can have an important role on the retention of an analyte and can 
change the selectivity of certain analytes. 
 
Fig. 1 Skeleton of Normal and Reverse phases 
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Certain limitations of RP-HPLC are: 
• Compounds much more polar than the compound of interest may be masked 
(eluted together) in the solvent front / void volume. 
• Compounds very less polar than the analyte may elute either late during the 
chromatographic run or are retained in the column. 
• The compounds with lower UV extinction coefficients or different 
wavelengths maxima may not be detectable at the low level. 
Reverse phase chromatography is widely in use due to the following advantages10 
• Many compounds such as biologically active substance, have limited 
solubility in non-polar solvent that are employed in normal phase 
chromatography. 
• Ionic or high polar compounds have high heats of adsorption on straight silica 
or alumina columns and therefore can elute as a tailing peaks. 
• Column deactivation from polar modifiers is a problem in liquid – solid 
chromatography. 
B) Size exclusion chromatography 
 It is also known as gel permeation or filtration chromatography.  Here, 
separation is based on the molecular size or hydrodynamic volume of the components. 
C) Ion Exchange Chromatography 
The stationary phase is an ion exchange resin, and separations are governed by 
the strength of the interactions between solute ions and the exchange sites on the 
resin. 
D) Ion pair /Affinity chromatography 
Separation is based on chemical interaction, specific to the target species. The 
more popular reverse phase mode uses a buffer and an added counter ion of opposite 
charge to the sample with separation being influenced by pH, ion strength, 
temperature, concentration and organic modifier. 
E) Chiral Chromatography 
Chirality plays an important role in pharmaceutical industry. It is mainly 
because of the enantiomers exhibit different pharmacological and toxicological 
properties in living systems.  
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INSTRUMENTATION 
The essential parts of apparatus for the High Performance Liquid Chromatography 
are: 
            1) Solvent reservior  
            2) Mobile phase 
            3) Pump system 
            4) Sample Injection System 
            5) Column 
            6) Detector 
 
1. Solvent reservoir  
 A modern HPLC apparatus is equipped with one or more glass or stainless 
steel reservoirs. The reservoir is often equipped with an online degasser which 
removes the dissolved gasses usually oxygen and nitrogen, which interfere by forming 
bubbles. Degasser may consist of vacuum pumping system, distillation system, 
system devices for heating, and solvent stirrer. 
2. Mobile phase 
 One of the greatest advantages of HPLC is versatility afforded by liquid 
mobile phase.  Sufficient solubility of solute molecules in the mobile phase must be 
ensured in order to prevent precipitation. 
 For the mobile phase, first variable to be decided is whether an organic or 
aqueous eluent should be used. With RP-HPLC analysis, either an aqueous eluent or 
variety of organic solvents such as methanol or acetonitrile is tried first. If the k 
values are too large with an aqueous solvent, then the separation should be attempted 
by using mixture, in various proportions. Many simple analyses can be carried out 
with isocratic elution using an aqueous eluent to which an organic modifier is added.  
If the sample to be analyzed contains a very complex mixtures or mixture of 
compounds of diverse structure and retention behavior, then either a ternary mixture 
of solvents can be used isocratically or gradient elution may be necessary. 
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3. Pumping system11 
 The function of the pump in HPLC is to pass mobile phase through the column 
at a controlled flow rate.  Features of an ideal pumping system include: 
• Generating pressure upto 6000 psi. 
• Pulse free output. 
• Flow rates ranging from 0.1 to 10 ml/min. 
• Flow control and reproducibility of 0.5% relative or better. 
• Corrosion resistant components. 
There are three types of pumps commonly used 
 Reciprocating pumps 
 Displacement pumps 
 Pneumatic pumps 
4.  Sample injection system 
 The limiting factor in the precision of LC measurements lie in reproducibility 
with which samples are introduced into the column packing. The earliest and simple 
means of sample introduction was syringe injection through a self-sealing elastomeric 
septum.  In stop flow injections, the flow of solvent is stopped momentarily, and 
fitting at column head is removed and the sample is injected directly into the head of 
column packing.  After replacing the fitting the system is again pressurized.  
 Commercial chromatographs use valves for sample injection. With these 
devices, sample is first transferred at atmospheric pressure from a syringe into a 
sample loop. Turning the valve from load to inject position connects the sample loop 
into the high-pressure mobile phase stream, whereby the contents of the sample loop 
are transferred on to the column. 
 In Rheodyne 7125 valve, sample from a microlitre syringe is loaded into the 
needle port, filling the sample loop, which is a small piece of stainless steel tube 
connected between ports.  Any excess goes to waste from another port.  On turning to 
‘inject’, the loop contents are flushed on to the column.  A variety of loop volumes is 
available, commonly 10-50 µl. 
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Fig.3 Load the sample 
 
 
 
 
Fig.4 Inject the sample 
 
5. Columns11 
 The columns most commonly used are made with 316-grade stainless steel (a 
Cr-Ni-Mo steel, relatively inert to chemical corrosion).  The inside of the stainless 
steel tube should be as smooth as possible, so the tubes are precision drilled or 
electro-polished after manufacture.  Common dimensions are 6.35 mm external 
diameter, 4.6 mm internal diameter and up to 25 cm long.  The columns can be 
packed with 10, 5, 4 or 3 µm diameter particles.   
 At the top of the column, there is a distributor for directing the injected sample 
to the center of the column and then a stainless steel gauze or frit on top of the 
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packing.  At the lower end there is another frit to retain the packing and then, for the 
4.6 mm type, a reducing union and a short length of 0.25 mm (0.01 in.) i.d. tubing to 
connect the column to the detector.  Materials other than stainless steel that are used 
for columns include glass, glass lined steel tube and polyethene or other inert plastics. 
 
Most chromatography suppliers now offer a range of plastic fittings that can 
be tightened to be leak free, by hand.  These are commonly made of Kel-F (PCFE) or 
Peek (a polyketone).  Peek has excellent chemical resistance to most organic and 
inorganic liquids (except H2SO4, HNO3 and tetrahydrofuran) and the tubing can be 
used at pressures up to 6000 psi for the smaller diameters. 
 
 
 
 
 
 
 
 
 
 
Fig.5 Properties of particles in various types of columns 
 
5.1 Analytical columns 
 The majority of LC columns range in length from 5 to 30 cm. The inner 
diameter of columns is often 4 to 5 mm.  Most common particle size of packing is 5 to 
10 µm.  Columns of this type contain 40000 - 60000 plates per meter. 
 
5.2 Preparative columns 
 Preparative columns are typically 2-5 cm in diameter and 25 cm long with 
packings of 15-100-µm diameter. Columns for large-scale work can be 20-30 cm in 
diameter and 60 cm long, using flow rates up to 1000 cc min-1.  The commercial 
systems can be used isocratically or with gradients and allow small-scale development 
and preparative separation to be done using the same system.   
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5.3 Guard columns 
 Usually, a short guard column is introduced before the analytical column to 
increase its life.  It removes particulate matter, contaminants from the solvents and 
also sample components that bind irreversibly to stationary phase. The composition of 
the guard column packing should be closely similar to that of analytical column. 
 
Table-3 
COLUMN DIMENSIONS 
TYPE INTERNAL 
DIAMETER 
(CM) 
LENGTH (CM) PARTICLE 
SIZE(CM) 
Analytical 
 
0.3-0.46 3-28 3-10 
Semi micro 
 
0.1-0.21 10-25 3-18 
Semi preparative 
 
0.8-1.0 10-25 5-10 
Preparative 
 
2.0-5.0 10-25 10-20 
6. DETECTORS12 
 The function of the detector in HPLC is to monitor the mobile phase emerging 
from the column.  The output of the detector is an electrical signal that is proportional 
to some property of the mobile phase and/or the solutes. 
LC detectors are basically of two types. 
 Bulk property detectors respond to mobile phase bulk property such as 
refractive index, dielectric constant or density. Solute property detectors respond to 
some property of solutes, such as UV absorbing, fluorescence, diffusion current, 
which are not possessed by the mobile phase. 
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Most common HPLC detectors 
• UV-Visible absorbance detector (UV-VIS) 
• Photo-diode array detector (PDA) 
• Fluorescence detector 
• Electrochemical (ECD) 
• Refractive Index (RI) 
• Mass detectors (MS) 
• Conductometric detector 
• Chiral detector (Polarimetric & circular dichrosim) 
• Evaporative Light scattering detector (ELSD) 
• Radiochemical detector 
QUANTIFICATION 
Quantitative analysis using chromatography is based on calibration curves 
obtained from each of the substances analyzed.  Calibration is needed in all those 
cases in which a signal related to mass or concentration of a component in mixture, is 
obtained.  Chromatographic test methods use either external or internal standards for 
quantification.   
1. External standard method 
An external standard method is used when the standard is analyzed on a 
separated chromatogram from the sample.  Quantification is based on a comparison of 
the peak area / height (HPLC or GC) or spot intensity (TLC) of the sample to that of a 
reference standard of the analyte of interest.  
The external standard method is more appropriate for samples as follows: 
• Samples with a single target concentration and narrow concentration range, 
e.g., acceptance and release tests. Simple sample preparation procedure. 
• Increased baseline time for detection of potential extraneous peaks, e.g., 
impurities test.  
2. Internal standard method 
 With an internal standard method, compound of known purity that does 
not cause interference in the analysis is added to the sample mixture.  Quantification 
is based on the response ratio of compound of interest to the internal standard vs. the 
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response ratio of a similar preparation of the reference standard (HPLC or GC).  This 
technique is rarely used for TLC methods.  
 
The internal standard method is more appropriate for samples as follows: 
1. Complex sample preparation procedures, e.g., multiple extractions. 
2. Low concentration sample (sensitivity being an issue),                       
e.g., pharmacokinetic studies.   
3. Wide range of concentrations expected in the sample for analysis,         
e.g., pharmacokinetic studies. 
Selection of Internal Standard 
A compound added to a sample in known concentration to facilitate the 
qualitative identification or quantitative determination of the sample components. 
Internal standards (IS) - substance used as reference in quantitative analysis, the 
internal standard is first mixed with standard solutions, later it is added to the 
unknown, and the ratio of peak heights (or areas) of internal standard and analyte is 
used for quantitative analysis. 
3. Standard addition method 
Standard addition method are particularly useful for analyzing complex 
sample in which the likelihood of matrix effects is substantial. A standard addition 
method can take several forms, one of the most common forms involves adding one 
or more increments of a standard solution to sample aliquots of the same size. This 
process is often called spiking the sample. Each solution is then diluted to a fixed 
volume before measurement11.  
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VALIDATION 
GUIDELINES FOR ANALYTICAL METHOD VALIDATION 
Validation13 
Validation of an analytical method is the process by which it is established, by 
laboratory studies, that the performance characteristics of the method meet the 
requirements for the intended analytical applications 
Validation is defined as follows by different agencies 
Food and Drug administration (FDA) 
Establishing documentation evidence, which provides a high degree of 
assurance that specific process, will consistently produce a product meeting its 
predetermined specification and quality attributes. 
World Health Organization (WHO) 
Action of providing that any procedure, process, equipment, material, activity, 
or system actually leads to the expected results 
European Committee 
Action of providing in accordance with the principles of good manufacturing 
practice that any procedure, process, equipment, material, activity or system actually 
leads to the expected results. In brief validation is a key process for effective quality 
assurance. 
Reasons for Validation 
There are two important reasons for validating assays in the pharmaceutical 
industry. The first, and by for the most important, is that assay validation is an integral 
part of the quality-control system. The second is that current good manufacturing 
practice regulation requires assay validation. 
Steps followed for validation procedures 
1. Proposed protocols or parameters for validations are established. 
2. Experimental studies are conducted. 
3. Analytical results are evaluated. 
4. Statistical evaluation is carried out. 
5. Report is prepared documenting all the results. 
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Objective and Parameters of Analytical Method Validation 
             The primary objective of validation is to form a basis for written procedure 
for production and process control which are designed to assure that the products have 
the identity, strength, quality and purity they purport or are represented to possess 
quality, safety and efficacy must be designed to build into the product. Each step of 
the manufacturing process must be controlled to maximize the probability that the 
finished products meet all quality and design specification. 
ANALYTICAL METHOD DEVELOPMENT 
               Methods are developed for new products when no official methods are 
available.  Alternate methods for existing (non-Pharmacopoeia) products are 
developed to reduce the cost and time for better precision and ruggedness. Trial runs 
are conducted, method is optimized and validated.  When alternate method proposed 
is intended to replace the existing procedure, comparative laboratory data including 
merit and demerits are made available15. 
 
Steps of method development16,17 
                   Documentation starts at the very beginning of the development process, a 
system for full documentation of the development studies must be established. All 
data relating to these studies must be recorded in laboratory notebook or an electronic 
database. 
 
1. Analyte standard characterization 
a. All known information about the analyte and its structure is collected i.e., 
physical and chemical properties. 
b. The standard analyte (≈100% purity) is obtained.  Necessary arrangement is 
made for its proper storage (refrigerator, desicators and freezer). 
c. When multiple components are to be analyzed in the sample matrix, the 
number of components is noted, data is assembled and the availability of 
standards for each one is made. 
d. Only those methods (spectroscopic, MS, GC, HPLC etc.,) that are 
compatible with sample stability are considered. 
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2. Method requirement 
              The goals or requirements of the analytical method that need to be developed 
are considered and the analytical figures of merit are defined.  The required detection 
limits, selectivity, linearity, range, accuracy and precision are defined.  
3. Literature search and prior methodology 
            The literature for all types of information related to the analyte is surveyed. 
Such as synthesis, physical and chemical properties, solubility and relevant analytical 
methods.  Books, periodicals, chemical manufacturers and regulatory agency 
compendia such as USP / NF, AOAC and ASTM publications are reviewed. Chemical 
Abstracts Service (CAS) automated computerized literature searches are convenient. 
4. Choosing a method 
a) Using the information in the literatures and prints, methodology is adapted.  
The methods are modified wherever necessary. Sometimes it is necessary to 
acquire additional instrumentation to reproduce, modify, improve or validate 
existing methods for in-house analytes and samples. 
b) If there are no prior methods for the analyte in the literature, from analogy, the 
compounds that are similar in structure and chemical properties are 
investigated and are worked out. There is usually one compound for which 
analytical method already exist that is similar to the analyte of interest. 
5. Instrumental setup and initial studies 
The required instrumentation is setup.  Installation, operational and 
performance qualification of instrumentation using laboratory Standard Operating 
Procedures (SOP’s) are verified. Always new consumables (e.g. chemicals, solvents 
and gases) are used.  
The analyte standard in a suitable injection / introduction solution and in 
known concentrations and solvents are prepared.  It is important to start with an 
authentic, known standard rather than with a complex sample matrix.  If the sample is 
extremely close to the standard (e.g., bulk drug), then it is possible to start work with 
the actual sample. 
6. Optimization 
           During optimization one parameter is changed at a time and set of conditions 
are isolated, rather than using a trial and error approach.  Work has been done from an 
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organized methodical plan and every step is documented (in a lab notebook) in case of 
dead ends. 
7. Documentation of analytical figures of merit 
The originally determined analytical figures of merit limit of quantitation 
(LOQ), Limit of detection (LOD), linearity, time per analysis, cost, sample 
preparation etc., are documented. 
8. Evaluation of method development with actual samples 
The sample solution should lead to unequivocal, absolute identification of the 
analyte peak of interest apart from all other matrix components.  
9. Determination of percent recovery of actual sample and demonstration of 
quantitative sample analysis 
Percent recovery of spiked, authentic standard analyte into a sample matrix 
that is shown to contain no analyte is determined.  Reproducibility of recovery 
(average +/- standard deviation) from sample to sample and whether recovery has 
been optimized has been shown.  It is not necessary to obtain 100% recovery as long 
as the results are reproducible and known with a high degree of certainty. 
The validity of analytical method can be verified only by laboratory studies.  
Therefore documentation of the successful completion of such studies is a basic 
requirement for determining whether a method is suitable for its intended application. 
 
METHOD VALIDATION14 
This process consists of establishments of the performance characteristics and 
the limitation of the method. 
METHOD PERFORMANCE PARAMETERS ARE DETERMINED USING 
EQUIPMENT THAT IS: 
1. Within specification 
2.Working correctly 
3. Adequately calibrated 
METHOD VALIDATION IS REQUIRED WHEN: 
1. A new method is being developed 
2. Revision of the established method 
3. When established method are used in different laboratories and by different 
analysts etc. 
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4. Comparision of method 
5. When quality control indicates method changes 
PERFORMANCE CHARACTERISTICS EXAMINED WHEN CARRYING 
OUT METHOD VALIDATION ARE18: 
1. Accuracy 
2. Precision 
3. Specificity 
4. Selectivity 
5. Sensitivity 
6. Limit of detection. 
7. Limit of quantification 
8. Linearity and Range 
9. Ruggedness 
10.  Robustness 
11. System suitability 
 
1. Accuracy 
The accuracy is the closeness of the measured value to the true value for the 
sample. 
The ICH documents recommended that accuracy should be assessed using a 
minimum of nine determinations over a minimum of three concentrations levels the 
specified range (i.e, three concentrations and three replicates of each concentration). 
Accuracy was tested (% Recovery and % RSD of individual measurements) 
by analyzing samples at least in triplicate, at each level (80,100 and 120 % of label 
claim) is recommended. For each determination fresh samples were prepared and 
assay value is calculated. Recovery was calculated from regression equation obtained 
in linearity study. Accuracy was determined from the mean relative error for a set of 
replicate analysis (i.e. the difference between measured and nominal concentration) 
for spiked samples. 
2. Precision 
The precision of an analytical procedure expresses the closeness of agreement 
between series of measurements obtained from multiple sampling of the same 
homogenous sample under the prescribed conditions. 
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Precision of an analytical method is usually expressed as the standard 
deviation, relative standard deviation or coefficient of variations of a series of 
measurements. The ICH documents recommend the repeatability should be assessed 
using a minimum of nine determinations covering specified range of procedure. 
Precision may be measure of either the degree of reproducibility or of repeatability of 
the analytical method under normal operating conditions. 
Repeatability: 
Repeatability expresses the precision under the same operating conditions over 
a short interval of time. Repeatability is also termed intra –assay precision. 
Intermediate Precision:  
Intermediate precision expresses with in laboratories variations: different days, 
different analyst and different equipment. 
Reproducibility:  
 When the procedure is carried out by different analyst in different laboratories 
using different equipment, regents and laboratories setting. Reproducibility was 
determined by measuring repeatability and intermediate precision. Reproducibility is 
assessed by means of an inter-laboratory trial. 
 
3. Specificity 
An investigation of specificity should be conducted during the validation of 
identification tests, the determination of impurities. An ICH document defines 
specificity as the ability to assess unequivocally the analyte in the presence 
compounds that may be expected to products and matrix components. 
The definition has the following implications: 
Identification test:  
Suitable identification tests should be able to discriminate compounds of 
closely related structure which are likely to be present .Ensure identity of an analyte, 
the analyte should have no interference from other extraneous components and be 
well resolved from them. 
Purity Test: 
 To ensure that all the analytical procedures performed allow an accurate 
statement of the content of impurity of the content of impurity of an analyte i.e. 
related substances test, heavy metals, residual solvents etc. 
INTRODUCTION 
 
Dept of Pharmaceutical Analysis  Page 23 
 
Assay: 
To provide an exact result, this allows an accurate statement on the content or 
potency of the analyte in a sample. 
4. Selectivity: 
It is a procedure to detect qualitatively the analyte in the presence of 
compounds that may be expected to be present in the sample matrix or the ability of a 
separative method to resolve different compounds. It is the measure of the relative 
method location or two peaks. 
Determination of selectivity:   
Selectivity is determined be comparing the test results obtained on the analyte with or 
without addition of potentially interfering material. When such components are either 
unidentified or unavailable a measure of selectivity can be obtained by determining 
the recovery of a standard addition of pure analyte to a material containing a constant 
level of the other compounds. 
5. Sentivity: 
Sensitivity is the capacity of the test procedure to record small variation in 
concentration. It is the slope of the calibration curve. 
6. Limit of detection (LOD): 
It is the lowest amount of analyte in a sample that can be detected, but not 
necessarily quantities as an exact value, under the stated experimental conditions. The 
detection limit is usually expressed as the concentration of analyte (percentage parts 
per million) in the sample. 
Determination of detection limit 
For instrumental and non- instrumental methods detection limit is generally 
determined by the analysis of samples with known concentration of analyte and by 
establishing the minimum level at which the analyte can be reliably detected.  
LOD = 3 x SD / slope of calibration curve 
   SD = Standard deviation of intercepts 
7. Limit of quantification (LOQ): 
It is the lowest amount of analyte in a sample that can be determined with 
acceptable precision and accuracy under the stated experimental conditions. 
Quantification limit is expressed as the concentration of analyte (e.g: % ppm) in the 
sample. 
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Determination of quantification limit 
For instrumental and non- instrumental methods, the quantitation limit is 
generally determined by the analysis of samples with known concentration of analyte 
and by establishing the minimum level at which the analyte can be determined with 
acceptable accuracy and precision.  
LOQ = 10 x SD / slope of calibration curve 
SD = Standard deviation of intercepts 
 
 
 
Fig. 6 Limit of detection and Limit of quantification via signal to noise 
  
8. Linearity and Range 
 The linearity of an analytical procedure is its ability to obtain test results that 
are directly proportional to concentration of analyte in samples. The range of an 
analytical is the intervals between the upper and lower concentration of analyte in the 
sample for which it has been demonstrated that the analytical procedure has a suitable 
level of precision accuracy and linearity. 
Determination of linearity and range: 
These characteristics are determined by application of the procedure to a series 
of samples having analyte concentration spanning the claimed range of procedure. 
When the relationship between response and concentration is not linear, 
standardization may be providing by means of a calibration curve. The ICH 
recommends that for the establishment of linearity a minimum of five concentrations 
normally used. 
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9. Ruggedness 
Degree of reproducibility of test results obtained by the analysis of the same 
samples under a variety of condition such as different laboratories, different analysts, 
different instruments etc., normally expressed as the lack of influence on test results 
of operational and environmental variable of the analytical method.  
Ruggedness is a measurement of reproducibility of test results under the 
variation in condition normally expected from laboratory to laboratory and from 
analyst to analyst. Degree of representative of test results is then determined as a 
function of the assay variable. 
By analysis of aliquots from homogenous lots in different laboratories, by 
different analyst, using operational and environmental conditions that may differs but 
is still with in the specified parameter of the assay variable.  
10. Robustness 
 Robustness of an analytical method is measure of its capacity to remain 
unaffected small but deliberate variations in method parameters and provides an 
indication of its reliability during normal usage. 
Testing varying some or all condition: 
• Column temperature 
• pH of buffer in mobile phase 
• Flow rate 
• Wave length 
11. System Suitability19 
 System suitability tests are based on the concept that the equipment, 
electronics, analytical operations and samples constitute an integral system that can be 
evaluated as a whole.  
According to USP system suitability are an integral part of chromatographic 
methods. These tests verify that the resolution and reproducibility of the system are 
adequate for the analysis to be performed. One consequence of the evaluation of 
robustness and ruggedness should be that a series of system suitability parameters is 
established to ensure that the validity of the analytical method is maintained whenever 
used. 
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SYSTEM SUITABILITY SPECIFICATIONS: 
 
 
 
Fig.7 Typical chromatogram with examples of retention measurements 
 
Wx = Width of the peak determined at either 5% or 10% above baseline 
 f    = Distance between peak maximum and peak front at Wx 
to   = Elution time of void volume or non-retained components 
tr     = Retention time of the analyte, R 
tw  = Peak width measured at baseline of the extrapolated straight sides to baseline.  
 
The parameters that are affected by the changes in chromatographic conditions are, 
• Capacity factor (k’) 
• Peak asymmetry / tailing factor (As) 
• Column efficiency (N)  
• Selectivity (α) 
• Dead volume 
• Retention time  Rt 
• Retention volume Rv 
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a) Capacity factor (k') 
The capacity factor, K’ is related to the retention time is a reflection of the 
proportion time of a particular solute residues in the stationary phase as opposed to 
the mobile phase. Long retention times results in large valves of K’. The capacity 
factor K’ can be calculated for every peak defined in a chromatogram, using the 
following equations. 
     
 
                                            Moles of solute in stationary phase 
Capacity factor   K’ = ---------------------------------------------- 
                                             Moles of solute in mobile phase 
 
K' = (t R- t0) / t 0 
 
The capacity factor is a measure of the degree of retention of an analyte 
relative to an unretained peak, where tR is the retention time for the sample peak and to 
is the retention time for an unretained peak. 
Recommendations 
The peak should be well-resolved from other peaks and the void volume. 
Generally the value of k' is > 2. 
Precision / Injection repeatability (RSD) of < 1% for ‘n’ > 5 is desirable. 
 
b) Tailing factor (T) 
A measure of the symmetry of a peak, given by the following equation where 
W0.05 is the peak width at 5% height and f is the distance from peak front to apex point 
at 5% height. Ideally, peaks should be Gaussian in shape or totally symmetrical. 
 
T = W0.05 / 2f 
 
The accuracy of quantitation decreases with increase in peak tailing because of 
the difficulties encountered by the integrator in determining where/when the peak 
ends and hence the calculation of the area under the peak. Integrator variables are 
preset by the analyst for optimum calculation of the area for the peak of interest. 
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Recommendations 
T of </= 2    is preferred 
 
c) Theoretical plate number / Efficiency (N) 
A measure of peak band spreading determined by various methods, some of 
which are sensitive to peak asymmetry. The most common are shown here, with the 
ones most sensitive to peak shape shown first: 
 
• 4-sigma / tangential 
N = 16 (tR / W)2 = L / H 
 
• Half height 
N = 5.54 (tR/ W) 2 = L / H 
Theoretical plate number is a measure of column efficiency .Theoretical plate 
number is a measure of column efficiency, that is, how many peaks can be located per 
unit run-time of the chromatogram, where tR is the retention time for the sample peak 
and W is the peak width. 
N is fairly constant for each peak on a chromatogram with a fixed set of 
operating conditions H, or HETP, the height equivalent of a theoretical plate, 
measures the column efficiency per unit length (L) of the column. Parameters which 
can affect N or H include peak position, particle size in column, flow-rate of mobile 
phase, column temperature, viscosity of mobile phase, and molecular weight of the 
analyte.  
Recommendations 
The theoretical plate number depends on elution time but in general should be 
> 2000. 
d) Resolution (Rs)  
Ability of a column to separate chromatographic peaks, Resolution can be 
improved by increasing column length, decreasing particle size, increasing 
temperature, changing the eluent or stationary phase. It can also be expressed in terms 
of the separation of the apex of two peaks divided by the tangential width average of 
the peaks. 
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Fig.8 Resolution Chromatogram 
 
 
RS = (tR2-tR1) / 0.5(w1+w2) 
 
Where tR1 & tR2 are the Retention time of the two compounds and w1 & w2 are 
the width of the two compounds. For reliable quantitation, well-separated peaks are 
essential for quantitation.  
Recommendations 
Rs of> 2 between the peak of interest and the closest potential interfering peak 
(impurity, excipient, degradation product, internal standard, etc.) are desirable. 
e) Dead Volume 
Dead Volume means any empty space or unoccupied volume, the presence of 
which can lead to disastrous losses in efficiency.  There will be dead volume in the 
column itself, which will be the space that is not occupied by the stationary phase.  
The other sources of dead volume are the injection unit, the tubing and fittings at each 
end of the column and the detector cell.   
f) Retention time (Rt)    
Retention time is the difference in time between the point of injection and 
appearance of peak maxima. Retention time is the time required for 50% of a 
component to be eluted from a column. Retention time is measured in minutes of 
seconds. Retention time is also proportional to the distance moved on a chart paper, 
which can be measured in cm or mm. 
g) Retention volume (Rv)   
Retention volume is the mobile required to elute 50% of the component from 
the column. It is the product of retention time and flow rate. 
                                Retention Volume = Retention time x flow rate 
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STATISTICAL PARAMETERS 
 
Statistics consists of a set of methods and rules for organizing and interpreting 
observations. The precision or reproducibility of the analytical method was 
determined by repeating the analysis six times and the following statistical parameters 
were calculated. 
 
Statistical procedures and representative calculations 
The consistency and suitability of the developed method are substantiated 
through the statistical analysis like standard deviation, relative standard deviation and 
theoretical plates per meter. 
 
Mean : 
Best estimation of the population mean mcg/ml for random samples from a 
population. 
ࢄ ൌ 
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Where  
X = Mean 
x = Individual observed valve 
n = Number of observation  
STANDARD DEVIATION: 
Standard deviation, σ= 1
)xx( 2i
−
−∑
n  
Where, 
                  x = sample, 
  xi = mean value of samples,  
                  n = number of samples 
Relative Standard Deviation =  σ/xi × 100 
Sandell, sensitivity (µg/cm2/0.001 absorbance units) = C/A×0.001 
Where, 
                 C= concentration of drug, 
                 A= Absorbance of drug 
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Standard error 
 It provides a measure of how well a sample mean approximates the population 
mean. Less value is more accurate 
SE = SD/v n 
Correlation:  (Fit of regression line) 
Purpose: 
Measurement of the relation between two or more variables / measures how 
close the points are to the regression line. 
Correlation co-efficient can range from -1.00 + 1.00 
Correlation value denotes with the letter r  
n(∑xy) – (∑x) (∑y) 
r  =   ___________________________ 
√ (n∑x2 – (∑x)2 (n∑y2 – (∑y)2 
Regression: 
Purpose:  
1. When the concentration range is so wide that the errors, both random and 
systematic, are not independent (which is assumption). 
2. When pairing is inappropriate for other reason, notably a long time span 
between two analysis (sample aging, change in laboratory conditions etc.)                                 
Regression line  
   Y = mx + b 
Where, 
  b  = intercept of the line with the  Y axis 
  m  = Slope (tangent) 
Slope m  
  n(∑xy) – (∑x)(∑y) 
 m = ---------------------------- 
  n(∑(x2)) – (∑x)2 
Intercept b  
 
(∑y)( ∑(x2) - (∑x)(∑xy) 
b =        ---------------------------- 
       n(∑(x2)) – (∑x)2 
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HPLC method validation 
Everyday many chromatographers face the need to develop a HPLC separation 
whereas individual approaches may exhibit considerable diversity; method 
development often follows the series of steps summarized in the following fig. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Validation method for release to routine laboratory 
 
                      Fig.9 Steps involved in HPLC method validation 
 
 
 
 
1. Introduction on sample 
Define separation goals 
2.    Need    for    special   HPLC 
Procedure, sample, pretreatment, etc
3.   Choose detector and Detector settings 
4. Choose LC method; 
  Preliminary run; estimate 
best separation conditions 
5. Optimize separation 
condition 
6. Check for problems or requirementsfor special 
procedure 
7c.Qualitative 
method 
7b.Quantitative 
calibration
7a. Recover 
purified material
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METHODS USED FOR THE EXAMINATION OF PHARMACEUTICAL 
MATERIAL MAY BE BROADLY CLASSIFIED AS FOLLOWS20,21 
 
Class A: 
Tests designed to establish identity, whether of bulk drug substances or have a 
particular ingredient in a finished dosage form. 
Class B: 
Methods designed to detect and quantitate impurities in a bulk drug substances 
or finished dosage form. 
Class C:  
Methods used to determine quantitatively the concentration of bulk drug 
substance or of a major ingredient in a finished dosage form. 
Class D:  
Methods used assess the characteristics of finished dosage forms such as 
dissolution profile and content uniformity. 
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TABLE-4 
CHARACTERISTIC THAT SHOULD BE CONSIDERED FOR DIFFERENT 
TYPES OF ANALYTICAL PROCEDURE 
(As per WHO guidelines) 
S.No Parameters Class A Class B Class C Class D 
Quantitative 
Tests 
Limit 
Tests 
1. Accuracy - Yes - Yes Yes 
2. Precision - Yes - Yes Yes 
3. Robustness - Yes Yes Yes Yes 
4. Linearity and range - Yes - Yes Yes 
5. Selectivity Yes Yes Yes Yes Yes 
6. Limit of detection Yes - Yes - - 
7. Limit of 
quantification 
- Yes - - - 
 
TABLE-5 
PARAMETERS 
S.No Goal Comment 
1. Resolution Precise and rugged quantitative analysis requires 
Resolution >1.5 
2. Separation <5-10 min 
3. Quantitation RSD <1.0% for assays; <5% for trace analysis 
4. Pressure <150kgf/cm2 is desirable, <200kgf/cm2 is usually 
essential 
5. Peak Shape  Narrow peaks  
6. Solvent 
consumption  
Minimum mobile phase usage per run is desirable 
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LEARN ABOUT CANCER22 
What is cancer? 
Cancer is the general name for a group of more than 100 diseases in which 
cells in a part of the body begin to grow out of control. Although there are many kinds 
of cancer, they all start because abnormal cells grow out of control. Untreated cancers 
can cause serious illness and even death. 
Normal cells in body 
The body is made up of trillions of living cells. Normally body cells grow, 
divide, and die in an orderly fashion. During the early years of a person’s life, normal 
cells divide faster to allow the person to grow. After the person becomes an adult, 
most cells divide only to replace worn-out or dying cells or to repair injuries. 
How cancer starts:- 
Cancer starts when cells in a part of the body start to grow out of control. 
Cancer cell growth is different from normal cell growth. Instead of dying, cancer cells 
continue to grow and form new, abnormal cells. Cancer cells can also invade other 
tissues, something that normal cells cannot do. Growing out of control and invading 
other tissues are what makes a cell a cancer cell. Cells become cancer cells because of 
damage to DNA. 
Tumors that are not cancer 
Not all tumors are cancerous. Tumors that aren’t cancer are called benign. 
Benign tumors can cause problems-they can grow very large and press on health 
organs and tissues. But they cannot grow into (invade) other tissues. Because they 
can’t invade, they also can’t spread to other parts of the body (metastasize).These 
tumors are almost never life threatening. 
Cancer types 
• Adrenal cortical cancer 
• Anal cancer 
• Bladder cancer 
• Bone cancer 
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• Breast cancer 
• Cervical cancer 
• Endometrial cancer 
• Eye cancer 
• Gallbladder cancer 
• Kidney cancer 
• Liver cancer 
• Lung cancer- non-small cell 
• Lung cancer- small cell 
Erlotinib23 
(er-lot-tin-nib) 
Trade/other name: Tarceva, OSI-774 
How does this drug work? 
Erlotinib is a type of targeted therapy known as a tyrosine kinase inhibitor. Its 
target is a tyrosine kinase protein called epidermal growth factor receptor (EGFR), 
which is located on the surface of certain cells in the body. Some cancers have higher 
than normal number of these receptors on their surfaces. Erlotinib blocks the receptor 
so that it can’t signal the cell to divide and grow. 
Interactions with other drugs 
The following drugs can cause Erlotinib to build up in the body, raising the risk 
of serious side effects: 
• The antidepressant nefazodone (serzone), fluvoxamine (luvox) 
• HIV drugs such as indinavir, ritonavir, fosamprenavir, nelfinavir, atazanavir, 
and others 
• Anti-seizure drugs carbamazepine (Tegretol). Phenobarbital (luminal) and 
phenytoin (dilantin). 
• TB drug rifampin (Rifadin, Rimactance;also in Rifamate And Rifater), 
andrifabutin (mycobutin) 
• The steroid drug dexamethasone (decadron). 
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• Any H2 blocker such as cimetidine (tagamet), ranitidine (zantac), famotidine 
(pepcid) or nizatidine (axid). 
Interactions with foods 
Taking this drug with food can raise the levels of the drug in the body, so it 
should be taken on an empty stomach. 
How is this drug taken or given? 
Erlotinib is in pill form, and is taken by mouth, once a day. The dose depends 
on a number of factors, including the type of cancer being treated. 
Possible side effects 
Common 
• Skin rash on face, neck, and trunk, diarrhea. 
• Feeling tired 
Less common 
• Shortness of breath 
• Cough 
Rare: 
• Eye irritation  
• Abdominal pain 
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DRUG PROFILE24 
 
Name     : ERLOTINIB 
Structure   :  
 
Chemistry: 
Chemical Name : N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)4-    
    quinazolinamine hydrochloride.     
Molecular Formula : C22H23N3O4.HCl 
Molecular Weight : 429.90 
Description    : white to cream coloured , amorphous powder. 
PKa    : 5.42 at 25°c 
Solubility   : Very slightly soluble in water, slightly soluble in        
    methanol,practically  insoluble  in acetonitrile,acetone,   
    ethyl acetate and hexane.     
Mechanism of action  : Selective epidermalgrowth factor receptor tyrosine   
    kinase inhibitor. 
Contraindication : Monotherapy for the treatment of patients with locally  
    advanced or  metastatic  non-small cell lung  cancer. 
Bulk density  : 0.1899 g/ml 
Tapped density : 0.3331g/ml 
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PHARMACOKINETICS 
 
Oral absorption : Erlotinib is about 60%absorbed after oral  
administration and its bioavailability is substantially  
         increased by food to almost  100%. 
Distribution  : Peak plasma levels is 3 to 4 hrs after oral administration 
    Steady state achieved in 7-8 days. 
    Crosses blood brain barrier. 
    Plasma protein binding 93%  to albumin and alpha-1 
    acid glycoprotein  (AAG) 
Metabolism  : Primarily  hepatic via CYP3A4,lesser extent by      
    CYP1A2 and extra hepatic isoform CYP1A1 
Excreation   : Excreation predominantly via feces(83%),urine   
    8%. Elemination half life 36.2 hrs. 
Adverse effects : Rash/acne,diarrohea. 
Dosing     : Daily dose of erlotinib is 150mg atleast one hour before  
    or 2 hrs after ingestion  of food. When dose reduction is                         
    necessary, should be reduced in 50mg. 
    Elderly no dose adjustment  is required.                                                   
Interaction      : CYP3A4 inhibitors (phenytoin, carbamazepine) 
    CYP3A4 inducers   (rifampicin)                            
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LITERATURE REVIEW 
Chahbouni A25et.al:developed and validated liquid chromatography (LC)-mass 
spectrometry (MS)/MS method in human plasma for the tyrosine kinase inhibitors 
erlotinib, gefitinib, and imatinib in human plasma. Pre-treatment of the samples was 
achieved by using liquid-liquid extraction and imatinib as internal standard. 
Separation was performed on a Waters Alliance 2795 LC system using an XBridge 
RP18 column. The mass spectrometer Micromass was equipped with an electro spray 
ionization probe, operating in the positive mode. The calibration curves in plasma 
were linear for erlotinib, gefitinib, and imatinib over the concentration range of 5 to 
3,000; 5 to 3,000, and 5 to 5,000 ng/mL, respectively. The intraday and interday 
accuracy ranged from 90% to 110% and the intraday and interday precision of the 
method was within 5%.  
 
R. Honeywell26et.al:developed a simple and selective method for the determination 
of various tyrosine kinase inhibitors by liquid chromatography tandem mass 
spectrometry. Utilizing a simple protein precipitation with acetonitrile a 20 μl sample 
volume of biological matrixes can be extracted at 4 °C with minimal effort. After 
centrifugation the sample extract is introduced directly onto the LC–MS/MS system 
without further clean-up and assayed across a linear range of 1–4000 ng/ml. 
Chromatography was performed using a Dionex Ultimate 3000 with a Phenomenex 
prodigy ODS3 (2.0 mm × 100 mm, 3 μm) column and eluted at 200 μl/min with a 
tertiary mobile phase consisting of 20 mM ammonium acetate: acetonitrile: methanol 
(2.5:6.7:8.3%). Injection volume varied from 0.1 μl to 1 μl depending on the 
concentration of the drug. Samples were observed to be stable for a maximum of 48 h 
after extraction when kept at 4 °C. Detection was performed using a turbo-spray 
ionization source and mass spectrometric positive multi-reaction-monitoring-mode 
(+MRM) for Gefitinib (447.1 m/z; 127.9 m/z), Erlotinib (393.9 m/z; 278.2 m/z), 
Sunitinib (399.1 m/z; 283.1 m/z) and Sorafenib (465.0 m/z; 251.9 m/z) at an ion 
voltage of +3500 V. The accuracy, precision and limit-of-quantification (LOQ) from 
cell culture medium were as follows: Gefitinib: 100.2 ± 3.8%, 11.2 nM; Erlotinib: 
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101.6 ± 3.7%, 12.7 nM; Sunitinib: 100.8 ± 4.3%, 12.6 nM; Sorafenib: 93.9 ± 3.0%, 
10.8 nM, respectively. This was reproducible for plasma, whole blood, and serum. 
The method was observed to be linear between the LOQ and 4000 ng/ml for each 
analyte.  
 
V.Rajesh27et.al:developed a simple, specific and precise high performance thin layer 
chromatographic method for estimation of Erlotinib hydrochloride as bulk drug. The 
chromatographic development was carried out on precoated silica gel 60 F254 
aluminium plates using mixture of Methanol: Ammonia (8:0.2 v/v) as mobile phase 
and densitometric evaluation of band was carried out at 250 nm using Camag TLC 
Scanner-3 with win CAT 1.4.3 version software. The RF value of drug was found to 
be 0.52 ± 0.01. The method was validated with respect to linearity, accuracy, 
precision and robustness. The calibration curve was found to be linear over a range of 
200- 1200 ng/ band. The % assay (Mean ± S.D.) was found to be 101.3 ± 1.02. The 
proposed HPTLC method was found to provide a faster and cost effective quantitative 
control for routine analysis of Erlotinib hydrochloride as bulk drug. 
 
Faivre L, Gomo C28et.al:developed a simple HPLC-UV method for the simultaneous 
quantification of gefitinib and erlotinib in human plasma. Gefitinib and erlotinib are 
two oral tyrosine kinase inhibitors (TKI). Following liquid-liquid extraction, gefitinib, 
erlotinib and sorafenib (internal standard), were separated with gradient elution using 
C8 column and mobile phase of acetonitrile/20mM ammonium acetate pH 4.5. 
Samples were eluted at a flow rate of 0.4 ml/min throughout the 15-min run. Dual UV 
wavelength mode was used, with gefitinib and erlotinib monitored at 331 nm, and 
sorafenib at 249 nm. The calibration was linear in the range 20-1000 ng/ml and 80-
4000 ng/ml for gefitinib and erlotinib, respectively. Inter- and intra-day precision 
were less than 7.2% and 7.6% for gefitinib and erlotinib, respectively. 
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G.Usha Rani29et.al:developed and validated extractive  colorimetric method  for 
estimation of erlotinib in bulk and tablet dosage form. Two simple, rapid sensitive, 
precise and economic spectrophotometric methods for the estimation of erlotinib. The 
solution of the drug formed colored ion-pair complexes with Bromocresol Green 
(BCG) and Methyl Orange (MO) in phosphate buffer pH 2.5, and extracted in 
chloroform.The complex of etoricoxib with BCG and MO showed λ max at 418.5nm 
and 424.4nm respectively. The complex was stable up to 22 hrs and obeyed Beer’s 
law over the concentration ranges of 10-1000 ug/ml. Correlation coefficient was 
found to be 0.9985.    
 
M.Padmalatha30et.al:developed a spectrophotometric method for the determination 
of erlotinib  in pure and pharmaceutical dosage form. The developed methods were 
based on reaction of erlotinib with Phenol red, BromoCresolGreen and Erichrome 
black T. They are quantified spectrophotometrically at their absorption maximum at 
418nm (MethodA), 424nm (MethodB) and 333nm (MethodC). Beer’s law was 
obeyed in the concentration range of 40-80ug/ml, 20-40ug/ml and 10-50ug/ml for the 
three method respectively. The colors were found to be stable for more than 4 hrs. 
 
V.Kalyana Chakravarthy31et.al:development  and validated of RP HPLC method 
for estimation of erlotinib in bulk and its pharmaceutical formulation. A RP-LC 
method used a kromasil 100-5,C18(150mm×4.6mmi.d;particle size 5um) and 
potassium dihydrogen phosphate buffer pH 2.4: acetonitrile : methanol(65:21:14 ) as 
eluent at flow rate 1.5ml/min with UV detection  at 250 nm. The erlotinib content was 
linear over a range of 75.02 to 225.06 ug/ml. The method precision for the 
determination of assay was below 2.0 %RSD. The percentage recoveries of active 
pharmaceutical ingredients from dosage forms ranged from 100.5 to 101.1. 
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G.Vidya Sagar32et.at:developed and validated a simple, accurate and cost efficient 
spectrophotometric method, for the estimation of erlotinib in tablet dosage form. The 
optimum conditions for the analysis of the drug were established. The maximum 
wave length (λmax) was found to be 247 nm. The percentage recovery of erlotinib 
was in the range of 99.7±0.12.Beer’s law was obeyed in the concentration range of 2-
10ug/ml. Calibration curves showed a linear relationship between the absorbance and 
concentration. 
 
M.Padmalatha33et.al:developed and validated High Performance Liquid 
Chromatographic Method for the determination of Erlotinib. They used 250x4.6mm, 
5µ particle, IntersilODS-3V C18column with 0.03M potassium dihydrogen 
orthophosphate in water pH 3.2,  orthophosphoric acid acetonitrile (55:45),as mobile 
phase at a flow rate of 0.8 ml/min. PDA detection was performed at 
246.0nm.Injection volume was20µl.HPLC grade water, Acetonitrile(50:50v/v)was 
used as diluents. The method was validated for accuracy, precision, linearity, 
specificity and sensitivity. Total run time was 20min, erlotinib eluted  with retention 
time of 4.75min.Calibration plots were linear over the concentration range 5-40µg/ml. 
Intra and inter day relative standard deviation for erlotinib was less than 3.3 and 4.1% 
respectively. 
 
Luca Signor34et.al:reported analysis of erlotinib and its metabolites in rat tissue 
sections by MALDI quadrupole time-of- flight mass spectrometry. The analysis was 
carried out on rat tissue sections from liver, spleen and muscle. Following oral 
administration at a dose of 5mg/kg, Samples were analyzed by matrix assisted laser 
desorption ionization (MALDI) with mass spectrometry (MS) using a orthogonal 
quadrupole time of flight instrument. The presence of the parent compound and of its 
o-demethylated metabolites was confirmed in all tissues types and their absolute 
amounts calculated. In liver the intact drug was found to be 3.76ng/mg tissue, while in 
spleen and muscle 6-30 folds lower values. These results were compared with drug 
quantitation obtained by whole-body autoradiography, which was found to be similar. 
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Lutz Gotze35et.al:development and clinical  application of a LC/MS/MS method for 
simultaneous determination of various tyrosine kinase inhibitors in human plasma. 
Developed and validated a specific, simple and rapid quantification method for 
various TKI’s in human plasma. A simultaneous test for six TKI’s (erlotinib, 
imatinib,lapatinib, nilotinib, sorafenib, sunitinib) was developed using liquid 
chromatography tandem mass spectrometry in a multiple reaction monitoring mode. 
After protein precipitation the specimens were applied to the HPLC system and 
separated using a gradient of  acetonitrile containing 1% formic acid with 10mM 
ammonium formate on an analytic RP C18 column. The calibration range was 10-
1000ng/ml for sunitinib and 50-5000ng/ml for the other TKI’s with coefficient of 
determination ≤15% and the chromatographic run time was 12 min. Plasma 
specimens were stable for measurement for atleast 1 week at 4°c. 
 
S.S Pujeri36et.al:developed and validated stability – indicating chromatographic 
method for the assay of erlotinib active pharmaceutical ingredient  in the presence of 
its degradation products on a C18 column using a mobile phase of 0.01M 
ammoniumformate-acetonitrile-containing formic acid with a flow rate of 1.0ml/min. 
Selectivity was validated by subjecting the stock solution of erlotinib to acidic, basic, 
photolysis, oxidative and thermal degradation. The linearity range and values for limit 
of detection (LOD) and quantification (LOQ) were found to be 1-198, 0.33, and 
1.1ug/ml, respectively. The analysis of the tablet containing erlotinib was quite 
precise (relative standard deviation<1%). 
 
ErrinR.Lepper37et.al:developed and validated a high- performance Liquid 
Chromatographic (HPLC) assay with U.V detection  for the quantitative 
determination of erlotinib  in human plasma. Quantitative extraction was achieved by 
a single- solvent extraction involving a mixture of acetonitrile and n-butyl 
chloride(1:4v/v). Erlotinib and the internal standard hydrochloride salt (OSI-597) 
were seperated on a column packed with NOVA-PAK C18 material and a mobile 
phase composed of acetonitrile  and water, pH 2.0 (60:40,v/v).The column effluent 
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was monitored  with dual U.V detection at wavelengths of 348nm erlotinib and 
383nm  erlotinib hydrochloride. The calibration graph was linear in the range of 100-
4500ng/ml, with values for accuracy and precision ranging from 87.9 to 96.2% and 
2.13 to 5.10% respectively, for three different sets of quality control samples. 
 
Rasoulzadeh F38et.al:studied the mutual interaction of anticancer drug erlotinib 
hydrochloride with bovine serum albumin (BSA) using fluorescence and U.V /VIS 
spectroscopy. The BSA  solution(0.1Mm) was prepared daily in tris buffer (0.05mol-
1,ph=7.4) and treated at final concentration of 1.67x10-5M with different amount of 
erlotinib hydrochloride to obtain final concentration of 0,0.2,0.4,0.8,1,2,4,6,8,20 and 
42µm respectively. The mixture was allowed to stand for 5 min and the fluorescence 
quenching spectra were recorded at 298,303, 308 and 313k. It was found that erlotinib 
hydrochloride caused the fluorescence quenching of BSA by the formation of a BSA 
–ERLOTINIB HYDROCHLORIDE complex. The mechanism of the complex 
formation was then analysed by determination of the number of binding sites the 
apparent binding constant Ka, and calculation of the corresponding thermodynamic 
parameters. Such as the free energy (∆G), enthalpy (∆H) and entropy changes (∆S) at 
different temperatures. Results showed that binding of erlotinib hydrochloride to BSA 
was spontaneous and the hydrophobic forces played a major role in the complex 
formation. The distance r between donar (BSA) and the acceptor (ERLOTINIB 
HYDROCHLORIDE) was found to be less than 8nm. Non radioactive energy 
transferring and static quenching between these two molecules. The presence of single 
binding site on BSA and Ka values for the association of BSA with ERLOTINIB 
HYDROCHLORIDE increased by the increase in temperature. 
 
Jiongwei Pan39et.al:developed a novel bioanalytical method and validated for the 
quantitative determination of erlotinib in human plasma by using the supported liquid 
extraction (SLE), sample cleanup coupled with hydrophilic interaction liquid 
chromatography and tandemmass spectrometric detection (HILIC-MS/MS). The SLE 
extract could be directly injected into the HILIC-MS/MS system for analysis without 
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the solvent evaporation and reconstitution steps. Erlotinib was used as the internal 
standard. The SLE extraction recovery was 101.3%.The validated linear curve range 
was 2 to 2,000 ng/mL based on a sample volume of 0.100-mL, with a linear 
correlation coefficient of > 0.999. The validation results demonstrated that the present 
method gave a satisfactory precision and accuracy: intra-day CV < 5.9% (<8.4% for 
the lower limit of quantitation, LLOQ) with n = 6 and the accuracy of 98.0–106.0%; 
inter-day CV < 3.2% (<1.5% for LLOQ) with n = 18 and the accuracy of 100.0–
103.2%. A dilution factor of 10 with blank plasma was validated for partial volume 
analysis. The stability tests indicated that the erlotinib in human plasma is stable for 
three freeze-thaw cycles (100.0–104.5% of the nominal values), or 24-h ambient 
storage (100.0–\104.8% of the nominal values), or 227-day frozen storage at both -20 
ºC (91.5–94.5% of the nominal values) and -70 ºC (93.3–93.8% of the nominal 
values). The results also showed no significant matrix effect (<6.3%) even with direct 
injection of organic extract into the LC-MS/MS system. 
 
Fouad Chiadmi40et.al:developed and validated an isocratic high-performance liquid 
chromatographic method for the determination of erlotinib in human plasma with 
detection at 348 nm. Quinine was used as internal standard. A reversed-phase 
symmetry C18 column (250 mm x 4.6 mm, 5 μm), was equilibrated with a mobile 
phase composed of potassium dihydrogen phosphate 0.05M and acetonitrile (60:40, 
v/v) with a final pH of 4.8 and having a flow rate of 1 mL/minute. The elution time 
for erlotinib and internal standard was approximately 7.4 and 2.6 minutes, 
respectively. Calibration curves of erlotinib in human plasma were linear in the 
concentration range of 50-1,000 ng/mL. Limits of detection and quantification in 
plasma were 6.3 and 21 ng/mL, respectively. Intra- and inter-day relative standard 
deviation for erlotinib in plasma was less than 3.3 and 4.1%, respectively. 
 
Hanqing Li41 et.al: developed a new synthetic and differential antiproliferative 
activity of two active isomeric metabolites of Erlotinib were investigated. This 
synthetic process had demonstrated to avoid the unstable 4- chloro-quinazoline 
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intermediates and long procedures. New intermediates and final compounds were 
identified by 1H NMR, 13C NMR and their purities were determined by HPLC. Invitro 
proliferative assay indicates that these two metabolites possessed antiproliferative 
activity against some conventional tumor cell lines and EGFR tyrosine kinase over- 
expression tumor cell lines as compared to Erlotinib control and their antitumor 
activity in cellular level was reported. 
 
Han-Qing Li42et.al: developed and validated a new HPLC-UV method for the 
quantitative determination of epidermal growth facto rreceptor inhibitor erlotinib in 
the plasma of tumor bearing BALB/c nude mice. Erlotinib and its internal standard 
1-(3-((6,7-bis (2-methoxyethoxy) quinazolin-4-yl) amino) phenyl) ethanone were 
extracted from mice plasma samples using liquid-liquid extraction with a mixed 
solvent of methyl t-butyl ether and ethyl acetate (9:1, v/v). Luna C18 column (4.6 
mm×250 mm, 5 μm) with acetonitrile: 5 mM potassium phosphate buffer pH = 5.2 
(41:59, v/v) as the mobile phase. UV detector was set at the wavelength of 345 nm, 
and the flow rate was 1.0 mL/min. The calibration curve was linear over the range of 
20–10 000 ng/mL with acceptable intra- and inter-day precision and accuracy. The 
intra-day and inter-day precisions were within the range of 1.69%–5.66%, and the 
accuracies of intra- and inter-day assays were within the range of 105%–113%.The 
mean  recoveries were  85.2% and  96.1% for erlotinib and  internal standard, 
respectively. 
 
V.RAJESH43et.al: developed a simple and sensitive spectrofluorimetric method for 
the estimation of erlotinib hydrochloride in pure and pharmaceutical dosage forms. 
Erlotinib hydrochloride exhibits maximum fluorescence intensity in methanol and the 
Beer’s law was obeyed in the range of 1-5 µg/mL at an excitation wavelength (λex) of 
295 nm and an emission wavelength (λem) of 339 nm. Stability studies with respect 
to time and temperature were also carried out. The results obtained were in good 
agreement with the labelled amounts of the marketed formulations. This method has 
been statistically evaluated and found to be accurate and precise. 
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OBJECTIVE OF WORK 
The literature survey revealed that spectrophotometric method, HPTLC 
method and Reverse phase HPLC method were used for the determination of drug in 
the tablet dosage form and also for its determination in biological specimens. 
In the present study the aim was to develop a new RP HPLC method for the 
determination of the drug in tablet formulation and its validation. The plan of the 
work can be represented as follows. 
Plan of Work 
• To obtain through knowledge in practical HPLC method development. 
• To implement a step-by-step procedure for method development and to set 
initial chromatographic conditions for the assay of Erlotinib tablets. 
• To conduct trails for the initial chromatographic conditions and to find 
optimum conditions. 
• To validate the developed RP-HPLC method.                          
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EXPERIMENTAL DETAILS 
A simple and sensitive reverse phase HPLC method has been developed for 
the analysis of Erlotinib. The method utilizes sample preparation followed by 
separation on a  Develosil ODS HG-5, column 150mm length, 4.6mm inner diameter, 
with 5µm particle size. The analyte was monitored by UV detection at 246nm using 
an isocratic mode with buffer and methanol in the ratio 520:480v/v as mobile phase. 
The flow rate was set at 1.0ml/min. The retention time for the drug was at 4.540min. 
Calibration curves for Erlotinib was recorded.  
Equipment and Apparatus used: 
¾ Analytical balance  (Metller Toledo AG-245) 
¾ Waters LC system equipped with 2695 pump and 2996 photo diode array detector. 
¾ Chromatographic data software : EMPOWER 
¾ Develosil ODS HG-5, 150×4.6mm. 5µ column 
¾ Vacuum filter pump 
¾  Ultrasonicator   (sonarex) 
¾ Membrane  filter(0.45 and 0.2microns) 
¾ pH-Meter  ( Lab India) 
Chemicals and Reagents used: 
a) Acetonitrile (HPLC grade) 
b) Ortophosphoric acid (HPLC grade). 
c) Triethylamine (HPLC grade) 
d) Water (HPLC grade) 
e) Methanol (HPLC grade) 
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Reference standards: 
Erlotinib Hydrochloride --      Natco Chemical Division at Mekaguda (HYD) 
% purity                    -- 99.5% 
 
The reference standard was obtained as gift sample and the authenticity and 
purity of the sample was certified. 
Tablet used:  Tarceva  (Erlotinib- 25 mg) 
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METHOD DEVELOPMENT 
The objective of this experiment was to optimize the assay method for the 
estimation of Erlotinib.The trials were done to optimize the chromatographic 
conditions. 
Preparation of mobile phase and standard solution of the drug for trails:- 
The mobile phase was prepared with a composition according as indicated in 
the table no 6 for the purpose of different trails. The mobile phase was filtered 
through 0.4µ filter and sonicated. The mobile phase was used as a diluent to prepare 
the standard solution. 
   Standard solution was prepared for each trail in the respective mobile phase. 
Working standard solution of Erlotinib Hydrochloride: 
About 50 mg ofworking standard of Erlotinib Hydrochloride was weighed and 
transferred into a clean and dry 50 ml standard flask. The sample was dissolved in a 
small volume of mobile phase by sonication for about 10 min and the volume was 
made up with the mobile phase. (1000µg/ml).0.5 ml of the stock solution was pipetted 
into a10 ml standard flask and diluted to mark with mobile phase (concentration-50 
mcg/ml). 
The standard solution was injected into the column in each trail. The Retention 
time at each trail was determined. The column, mobile phase and results obtained in 
the trails have been indicated in the table 6. The table also reveals the result of the 
chromatograms in term of retention time. The trail no 5 employed was found to be 
satisfactory in which column Develosil ODS HG-5, mobile phase orthophosphoric 
acid, and triethylamine buffer: methanol (520:480) were used to obtain adequate 
results.    
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                                                                                                                  Table: 6 
 
DIFFERENT COMBINATIONS OF BUFFERED SOLVENT SYSTEM TRIED WITH DIFFERENT COLUMN IN TRAILS 
 
Sl.no/Trail.no Stationary phase Mobile phase Flow rate Temperature Wave 
length 
Retention 
time 
Remarks 
1. OEM Column, 
C18(250X4.6X5µ) 
Water :Methanol 
65 : 35 
1ml/min 40ºC 246 nm 16.043 Symmetric peak, 
More retention 
time 
2. Inertsil ODS C18 
(250X4.6X5µ) 
Water :Acetonitrile 
60: 40 
1ml/min 40ºC 246 nm 11.870 Small tailing 
 
3. Inertsil ODS C18 
(150X4.6X5µ) 
0.1M Ammonium 
Phosphate buffer: 
Acetonitrile 
40 : 60 
1ml/min 40ºC  
 
246 nm 
5.587 Less retention 
time 
4. Kromasil C18 
(150X4.6X5µ) 
Phosphate buffer : 
Acetonitrile : 
Methanol 
650 : 210 : 140 
1.5ml/min Ambient 250 nm 8.302 Peak broadening 
5. Develosil ODS 
HG- 5 
(250X4.6X5µ) 
Ortho phosphoric 
acid, Triethylamine 
buffer : Methanol 
520  : 480 
1ml/min 40ºC 246 nm 4.543 Well resolved 
 
Peak of Erlotinib was well resolved with the column Develosil ODS HG- 5 (250X4.6X5µ), with the solvent system of orthphosphoric 
acid, triethylamine buffer : methanol in the ratio of 520  : 480 as shown in following Fig 10. 
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Optimized method 
Preparation of Mobile phase: 
Preparation of buffer:  
The buffer solution was prepared by mixing 2 ml of triethylamine and 2 ml of 
orthophosphoric acid in water and the volume was madeup to 1000 ml. 
Preparation of mobile phase: 
The mobile phase was prepared by mixing buffer and methanol in the ratio 
520:480v/v respectively and filtered through 0.45µ filter. The mobile phase was then 
sonicated using Ultra-sonicator to remove the dissolved gases. 
Preparation of Diluent:  
Mobile phase was used as the diluent. 
Determination of Retention time: 
Preparation of Erlotinib Hydrochloride standard stocksolution: 
Working standard solution of Erlotinib Hydrochloride: 
About 50 mg ofworking standard of Erlotinib Hydrochloride was weighed and 
transferred into a clean and dry 50 ml standard flask, the sample was dissolved in a 
small volume of mobile phase  by sonication for about 10 min and the volume was 
made up with the mobile phase filtered through 0.45µ filter. (1000µg/ml).0.5 ml of 
the stock solution was pipetted into a10 ml standard flask and diluted to mark with 
mobile phase (concentration-50 mcg/ml). 
      50 mg Erlotinib Hydrochloride     50 ml (1000µg/ml) 
 
                                 0.5 ml             10 ml (50 µg/ml)                            
The retention time of Erlotinib Hydrochloride was found to be 4.540 min 
when injected and chromatograms are shown in the Fig.11 and Fig.12. 
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Application of standard method for the sample: 
Sample             :         Erlotinib tablet. 
Label claim   :         Erlotinib 25 mg. 
Mfg. by    :  Natco Pharma Pvt Limited. 
Preparation of working sample solution: 
Average weight of the tablet was computed from the weight of 20 tablets. The 
tablets were powdered. The tablet powder equivalent to 100 mg of Erlotinib was 
accurately weighed and transferred into a clean and dry 100 ml standard flask. The 
sample was dissolved in a small volume of mobile phase by sonication for about 10 
min and the volume was made up with the mobile phase. The solution was filtered by 
using Whatmann filter paper. (Concentration 1000µg/ml).0.5 ml of the stock solution 
was pipetted into a10 ml standard flask and diluted to mark with mobile phase. It was 
filtered through 0.45µ filter (Concentration-50 mcg/ml). 
  100 mg Erlotinib                           100 ml (1000µg/ml) 
 
   0.5 ml                    10 ml(50 µg/ml)                               
The sample was injected and chromatograms were recorded and shown in the Fig.13 
The amount of Erlotinib present in each tablet formulation was calculated by 
comparing the peak area of the test with that of the standard. 
Assay: 
Assay of formulation available in the market was carried by preparing the 
sample solution as indicated above procedure injected into HPLC system. The 
percentage purity was found out by using following formula. Recovery studies were 
also carried out. The results were discussed.  
 
  
METHOD DEVELOPMENT 
 
Dept of Pharmaceutical Analysis  Page 56 
 
The content of Erlotinib present in the tabletof average weight: 
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Where, 
AT  =  average area counts of sample preparation. 
AS =  average area counts of standard preparation. 
WS  =  weight of working standard taken in mg. 
P  =  Percentage purity of working standard 
LC  =  Label Claim 
TW = weight of sample taken 
Avgwt = average weight of tablet in mg 
393.9 = Molecular weight of Erlotinib 
429.9 = Molecular weight of Erlotinib hydrochloride 
Tablet average weight  45.8 mg  
Weight of standard  25.4 mg  
Weight of sample  42.6 mg  
Label claim   25 mg  
Stdpurity   99.5 %  
Factor for calculation:  393.9/429.9mg  
Avg.standard Area  2015.879   
Avg.sample area  2014.965 
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=     99.5%. 
The amount of Erlotinib present in the tablet of average weight  
= 99.5 / 100 X 25 
  = 24.875 mg. 
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VALIDATION 
Validation of analytical method for the assay of Erlotinib: 
            Validation of analytical method is a process to establish that the performance 
characteristics of the developed method meet the requirement of the intended 
analytical application.  
Design of the experiment: 
                Typical analytical parameters used in assay validation are: 
 
                                          METHOD VALIDATION 
 
1. SYSTEM SUITABILITY STUDIES 
2. SPECIFICITY 
3. LINEARITY AND RANGE 
4. PRECISION 
a) SYSTEM PRECISION 
b) METHOD PRECISION 
5. RUGGEDNESS 
6. ACCURACY 
7. ROBUSTNESS 
8. LOD 
9. LOQ 
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1. SYSTEM  SUITABILITY 
Preparation of standard stock solution: 
About 50 mg of working standard of Erlotinib Hydrochloride was weighed 
and transferred into a clean and dry 50 ml standard flask, the sample was dissolved in 
a small volume of mobile phase  by sonication for about 10 min and the volume was 
made up with the mobile phase. (1000µg/ml) 
0.5 ml of the stock solution was pipetted into a10 ml standard flask and diluted 
to mark with mobile phase (concentration-50 mcg/ml) and filtered through 0.45µ 
filter. 
Procedure:  
The standard solution was injected for five times and measured the area for all 
five injections in HPLC. The %RSD for the area of five replicate injections was found 
to be within the specified limits. The Chromatograms were shown in Fig.14. The 
results were discussed in the following table 7.   
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Table No. 7  
Data for System Suitability 
Injection tR Peak Area USP 
Plate count 
USP 
Tailing 
1 4.547 2036.567 6470 1.147 
2 4.553 2032.964 6865 1.65 
3 4.53 2036.427 6911 1.69 
4 4.55 2028.420 6932 1.69 
5 4.547 2037.567 6890 1.65 
Mean 4.5454 2034.389 6906.6 1.67 
SD 0.00896 3.7635222 46.418 0.02 
% RSD 0.20 0.18 0.672 1.43 
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2. Specificity 
The specificity of the method was evaluated by analyzing the sample solution 
spiked with the excipients at appropriate levels. The assay result was unaffected by 
the presence of extraneous materials. 
Preparation of placebo: 
Placebo is prepared by mixing all excipients with out active ingredients. 
Determination: 
About 100mg of placebo was weighed accurately and transferred in to 100 ml 
of volumetric flask, mixed thoroughly with sufficient mobile phase and the volume 
was made up to 100 ml with diluent. The solution was filtered. 0.5 ml of this solution 
was diluted to 10 ml with mobile phase. The solution was again filtered through 
millipore filter and 10 µl of this solution was injected and chromatogram was 
recorded shown in the Fig.15. 
 
About 50 mg of Erlotinib working standard was weighed accurately and 
transferred into 100 ml standard flask, dissolved in small volume of the mobile phase. 
100 mg of placebo was mixed with above solution and made up the volume with 
mobile phase, filtered through millipore filter, 10µl of this solution was injected and 
chromatogram was recorded shown in Fig.16, 17 and reports were shown in table 8. 
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Table No. 8 
Specificity for Erlotinib 
 
S.No Sample Area obtained %Content of drug 
w/v 
1 Standard 2037.567 99.81%w/v 
2 Standard + placebo 2028.420 99.43%w/v 
3 Placebo 0 0 
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3. LINEARITY AND RANGE 
Linearity was assessed by performing measurement at several analyte 
concentrations. A minimum five concentrations were recommended for linearity 
studies. 
 The linearity of an analytical method is its ability to show test results that is 
directly proportional to the concentration of analyte in sample with in a given range. 
The linearity of an analytical method was determined by mathematical treatment of 
test result obtained by analysis of samples with analyte concentration across claimed 
range of peak area Vs concentration is plotted and percentage curve fitting is 
calculated. 
    Acceptance  criteria    : Percentage curve fitting should not be less than 
99.7% 
 
Preparation of working standard solution 
Erlotinib was weighed accurately and stock solution was prepared. Different 
volumes of stock solution were diluted to get a concentration range of 10 to 60 µg/ml. 
Table No. 9 
  S. No Volume of stock 
solution taken (ml) 
Volumetric flask      
taken (ml)   
Concentration of    
Solution (mcg/ml) 
      1 0.1           10          10 
      2 0.2           10           20 
      3 0.3           10           30 
      4 0.4           10           40 
      5 0.5           10           50 
      6  0.6           10           60 
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Procedure: 
10µl of working standard solution were injected in duplicate and the 
chromatograms were recorded and shown in Fig.18 to 23. 
The correlation co-efficient and percentage curve fitting were calculated from 
the following formula. 
ࡾ ൌ 
૜ ሺ࢞ െ ࢞ഥሻ ૛ሺ࢟ െ ࢟ഥሻ ૛
ሺ࢔ െ ૚ሻࡿ࢞ ࡿ࢟
 
 
Where  
x = concentration 
y = instrumental response 
Sx=standard deviation of x 
             SY = standard deviation of y 
           Percentage curve fitting = 100 x correlation coefficient 
 
 
         Acceptance criteria 
: Correlation coefficient should not be less than 
0.99%  
: Curve fitting should not be less than   99.7% 
 
        The linearity data and analytical performance parameters of Erlotinib was shown 
in table and calibration curve of Erlotinib was shown in Fig.24. 
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Table No. 11 
Linearity results for Erlotinib 
 
 
Conc.(µg/ml) 
 
10 
 
20 
 
30 
 
40 
 
50 
 
60 
Peak area 464.112 861.433 1222.921 1612.944 2011.541 2395.321 
Correlation 0.999 
 
 
Table No. 12  
Calibration parameters for Erlotinib 
 
 
 
 
 
 
 
 
 
  
Parameter Results 
Slope 38.56 
Intercept 78.40 
Correlation co-efficient 0.999 
Percentage curve fitting 99.9 % 
                                                                                   METHOD VALIDATION 
 
Dept of Pharmaceutical Analysis  Page 67 
 
 
4. PRECISION 
Precision of an analytical method is the degree of agreement among individual 
test result when the procedure is applied repeatedly to multiple samplings of a 
homogenous sample. Precision of analytical method is usually expressed as the 
standard deviation or relative standard deviation. 
Determination: 
The precision of an analytical method was determined by assaying sufficient 
number of sample and relative standard deviation is calculated. 
The precision of the instrument is determined by assaying the samples 
consecutively number of times and relative standard deviation is calculated. 
      Acceptance criteria  :   The relative standard deviation should be with in 
2% 
 
 
A. SYSTEM PRECISION 
 
Preparation of standard solution: 
About 50 mg of working standard of Erlotinib Hydrochloride was weighed 
and transferred into a clean and dry 50 ml standard flask, the sample was dissolved in 
a small volume of mobile phase  by sonication for about 10 min and the volume was 
made up with the mobile phase. (1000µg/ml).0.5 ml of the stock solution was pipetted 
into a10 ml standard flask and diluted to mark with diluent and filtered through 0.45µ 
filter (concentration-50 mcg/ml). 
Procedure: 
The standard solution was injected for five times and measured the area for all 
five injections in HPLC. The %RSD for the area of five replicate injections was found 
to be within the specified limits. The Chromatograms were shown in Fig 25. The 
results were discussed in the Table 13, 14. 
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B.METHOD PRECISION 
Preparation of working sample solution  
               Average weight of the tablet was computed from the weight of 20 tablets. 
The tablets were powdered. The tablet powder equivalent to 100 mg of Erlotinib was 
accurately weighed and transferred into a clean and dry 100 ml standard flask. The 
sample was dissolved in a small volume of mobile phase by sonication for about 10 
min and the volume was made up with the mobile phase. The solution was filtered by 
using Whatmann filter paper (Concentration 1000µg/ml).0.5 ml of the stock solution 
was pipetted into a10 ml standard flask and diluted to mark with mobile phase and 
filtered through 0.45 µ filter (concentration-50 mcg/ml). 
Procedure: 
The sample solution was injected for five times and measured the area for all 
five injections in HPLC. The %RSD for the area of five replicate injections was found 
to be within the specified limits. The Chromatograms were shown in the Fig.26. The 
results were discussed in the Table 15,16. 
The standard deviation and relative standard deviation were calculated from statistical 
formula. 
Standard deviation (σ) =  1
)xx( 2i
−
−∑
n  
Where, 
  x = sample, 
xi = mean value of samples,  
n = number of samples 
Relative Standard Deviation (%) =   σ   /xi × 100 
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Table No. 13 
Precision data of the system 
Injection No Peak Area % Recovery 
1 2036.567 100.7 
2 2032.964 100.5 
3 2036.427 100.7 
4 2028.420 100.3 
5 2037.567 100.7 
Mean 2034.389 100.58 
SD 3.7635222 0.1789 
% RSD 0.18 0.18 
 
 
Table No. 14 
System precision report for Erlotinib 
 
 
 Relative standard deviation 
Erlotinib       Acceptance criteria 
              0.18 < 2.0% 
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Table No. 15 
Method precision of Erlotinib 
 
Injection no Peak Area % Recovery 
1 2018.593 100.1 
2 2014.965 99.96 
3 2013.985 99.92 
4 2015.879 100.0 
5 2011.118 100.3 
Mean 2017.031 100.056 
SD 3.140105 0.151912 
% RSD 0.16 0.15 
 
 
                                                      Table No. 16 
Method precision report for Erlotinib 
 
 
Relative standard deviation 
Erlotinib Acceptance criteria 
0.16 < 2.0% 
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5. RUGGEDNESS 
The ruggedness of an analytical method is degree of reproducibility of test 
result obtained by the analyst under a variety of normal test condition. Such as 
different laboratories, different analysts, different instruments, lots of reagents, 
different elapsed assay times, different temperature, different days etc. 
 
The ruggedness of an analytical method is determined by aliquots from 
homogenous lots by different analyst using operational and environmental conditions 
that may differ but are also with in the specified parameters of the assay. The degree 
of reproducibility of test results is then determined as function of the assay variables. 
This reproducibility may be compared with the precision of the assay under normal 
condition to obtain a measure of the ruggedness of the analytical method. The assay 
of Erlotinib was performed in different days. 
 
Procedure: 
Working standard solution and working sample solution of Erlotinib were 
prepared by different analyst and on different days and 10 µl of working sample 
solution was injected and chromatograms were recorded shown in Fig.27,28 and 
ruggedness of the method and report of  Erlotinib was shown in Table 17,18. 
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Table No. 17 
 Ruggedness results for Erlotinib: (Day-1, Analyst-1) 
 
Parameter Peak Area % Assay 
Avg 2054.018 99.68 
% RSD 0.04 0.43 
 
 
Table No. 18 
 Ruggedness results for Erlotinib: (Day-2, Analyst-2) 
Parameter Peak Area % Assay 
Avg 2056.393 100.865 
% RSD 0.03 0.26 
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6. ACCURACY 
 
The Accuracy of an analytical method is the closeness of the test result 
obtained by that method to the true value 
Accuracy is measured as the percentage of the analytes recovered by the 
assay. Spiked samples were prepared in triplicate at three intervals a range of 100-
150% of the target concentration, and injected into the HPLC system. 
Acceptance criteria : Percentage recovery should be within 90-110%w/w 
 
 
Preparation of Sample Stock Solution: 
 
               Average weight of the tablet was computed from the weight of 20 tablets. 
The tablets were powdered. The tablet powder equivalent to 100 mg of Erlotinib was 
accurately weighed and transferred into a clean and dry 100 ml standard flask The 
sample was dissolved in a small volume of mobile phase by sonication for about 10 
min and  the volume was made up with the mobile phase. The solution was filtered by 
using whatmann filter paper. (Concentration 1000µg/ml).0.5 ml of the stock solution 
was pipetted into a10 ml standard flask and diluted to mark with mobile phase and 
filtered through 0.45 µ filter. (Concentration-50 mcg/ml) 
 
The stock solution was diluted with mobile phase. Further to obtain a 
concentration ranging from 45mcg to 65 mcg/ml. The dilution made was shown in the 
Table 19. 
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Table No. 19 
S.NO From stock 
sample solution 
volume taken 
(ml) 
50 mcg/ml 
solution taken 
(ml) 
Volumetric flask 
taken (ml) 
Concentration of 
solution 
(mcg/ml) 
1 0.4 1 10 45 
2 0.5 1 10 55 
3 0.6 1 10 65 
 
 
 
Procedure: 
 
The standard solution, 45 mcg/ml, 55 mcg/ml and 65 mcg/ml solutions were 
separately injected into the HPLC.T he individual recovery and mean recovery values 
were calculated. The chromatograms were shown in Fig.29 to 32. The results were 
discussed in the Table 20. 
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Table No. 20 
Percentage Recovery data for Erlotinib 
 
 
 
 
 
 
 
 
 
  
S.No Spike 
Level 
Amount 
(µg / ml) 
added 
Amount 
(µg / ml) 
found 
% Recovery Mean % 
Recovery 
1 100 % 45 45.85 101.88 101.78 
100 % 45 45.77 101.77 
100 % 45 45.78 101.75 
2 125 % 55 54.8 99.68 99.77 
125 % 55 54.84 99.72 
125 % 55 54.87 99.77 
3 150 % 65 64.05 98.55 99.86 
150 % 65 64.23 98.81 
150 % 65 64.12 98.70 
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7. ROBUSTNESS 
Robustness of an analytical method is measure of its capacity to remain 
unaffected by small but deliberate variation in method parameters and provides on 
indication of its reliability during normal usage. 
Determination: 
The robustness of an analytical method is determined by analysis of aliquots 
from homogenous lots by differing physical parameters that may differ but are still 
with in the specified parameters of the assay. For example change in physical 
parameters like flow rate and wavelength. 
a) Effect of variation of Flow rate: 
A study was conducted to determine the effect of variation in flow rate by 
injecting 0.9 ml/min and 1.1ml/min. Sample solution was prepared and injected into 
the HPLC system. The retention time values were measured. The chromatograms 
were shown in the Fig. 33 to 35.The results were discussed in the Table 22 to 24. 
b) Effect of variation of wavelength: 
A study was conducted to determine the effect of variation in wavelength. 
Standard solution was prepared and injected into the HPLC system at 248nm and 
244nm. The effects of variation in wavelength were measured. The chromatograms 
were shown in the Fig.36 & 37.The results were discussed in the Table 25 to 28. 
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Table No. 21 
Chromatographic condition for Robustness 
Change in flow rate 0.9 ml/min 
 
Change in flow 0.9 ml/min 
Instrument HPLC Shimadzu Separation Module  LC -
20 AT Prominence Liquid 
Column Develosil ODS HG-5 250X4.6,5µm 
Wavelength 246nm 
Injection volume 10µl 
Column oven 40°c 
Run time 10min 
 
 
 
Table No. 22 
Report of Robustness 
 
Drug Average Rt in 
0.9ml/min 
Average Rt in 
1.0ml/min 
Average 
Asymmetry in 
0.9ml/min 
%RSD 
Erlotinib 5.180 4.540 1.105 0.019 
 
 
 
 
 
 
 
                                                                                   METHOD VALIDATION 
 
Dept of Pharmaceutical Analysis  Page 78 
 
 
Table No. 23 
Chromatographic condition for Robustness 
Change in flow rate 1.1 ml/min 
 
Change in flow 1.1 ml/min 
Instrument HPLC Shimadzu Separation Module  LC -20 AT 
Prominence Liquid 
Column Develosil ODS HG-5 250X4.6,5µm 
Wavelength 246nm 
Injection volume 10µl 
Column oven 40°c 
Run time 10min 
 
 
 
 
Table No. 24 
Report of Robustness 
 
Drug Average Rt in 
1.1ml/min 
Average Rt in 
1.0ml/min 
Average 
Asymmetry in 
1.1ml/min 
%RSD 
Erlotinib 4.113 4.540 1.161 0.21 
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Table No. 25 
Chromatographic condition for Robustness 
Change in wavelength 244 nm 
 
Change in Wavelength 244 nm 
Instrument HPLC Shimadzu Separation Module  LC -20 AT 
Prominence Liquid 
Column Develosil ODS HG-5 250X4.6,5µm 
Flow rate 1.0 ml/min 
Injection volume 10µl 
Column oven 40°c 
Run time 10min 
 
 
 
Table No. 26 
Report of Robustness 
 
Drug Average Rt in 
244 nm 
Average Rt in 
246 nm 
Average 
Asymmetry in 
244 nm 
%RSD 
Erlotinib 4.543 4.547 1.167 0.043 
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Table No. 27 
Chromatographic condition for Robustness 
Change in wavelength 248 nm 
 
Change in Wavelength 248 nm 
Instrument HPLC Shimadzu Separation Module  LC -20 AT 
Prominence Liquid 
Column Develosil ODS HG-5 250X4.6,5µm 
Flow rate 1.0 ml/min 
Injection volume 10µl 
Column oven 40°c 
Run time 10min 
 
 
Table No. 28 
Report of Robustness 
 
Drug Average Rt in 
248 nm 
Average Rt in 
246 nm 
Average 
Asymmetry in 
248 nm 
%RSD 
Erlotinib 4.543 4.547 1.114 0.015 
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Limit of Detection (LOD) 
It is the lowest amount of analyte in a sample that can be detected, but not 
necessarily quantities as an exact value, under the stated experimental conditions. The 
detection limit is usually expressed as the concentration of analyte (percentage parts 
per million) in the sample. 
          It is determined by based on the standard deviation of response and the slope. 
The detection limit may be expressed as 
The LOD was determined by the formula: 
LOD = 3.3 σ/ S 
Where 
σ =          standard deviation of the response 
S          = slope of calibration curve 
LOD    = 3.3 (0.00896/38) 
=  0.000766 µg/ml 
 
From the formula limit of detection was found to be = 0.000766 µg/ml 
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8. Limit of Quantification (LOQ) 
It is the lowest amount of analyte in a sample that can be determined with 
acceptable precision and accuracy under the stated experimental conditions. 
Quantification limit is expressed as the concentration of analyte (e.g: % ppm) in the 
sample. Which can be quantitated with suitable precision and accuracy. 
Based on the deviation of the response and the slope. 
Quantitation limit (QL) may be expressed as:  
 
                                                   LOQ = 10 σ/ S 
Where            
              σ         =         Standard deviation of the response 
              S      =         slope of calibration curve   
                       LOQ   = 10 (0.00896/38.56) 
=  0.002323 µg / ml. 
 
From the formula limit of quantitation was found to be =  0.002323 µg / ml. 
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RESULTS AND DISCUSSION 
Validation  of  analytical  method  for  determination  of  assay  of  Erlotinib  
25 mg  tablets  was  performed  for  the  parameters  including – Specificity,  
Linearity and  Range,  Precision (System  precision, Method  precision), Intermediate 
precision (Ruggedness), Accuracy and  Robustness. The summary of results obtained 
isappended below. 
 
Parameter 
 
Acceptance Criteria 
 
Results 
 
Specificity 
There should not be any 
interference from placebo, blank 
and main   peak. (Active) 
There is no interference 
from blank, placebo and 
sample peak. 
 
Linearity and  
Range 
Correlation coefficient should be 
not less than 0.995 over working 
range. 
 
Correlation coefficient 
= 0.9999. 
Precision 
Repeatability 
System  precision 
%RSD should   not   be 
more than   2.0% 
SD=0.1789 
%RSD=0.18 
Repeatability 
Method  precision 
 
%RSD  should  not  be  more  
than  2.0% 
SD=0.1519 
%RSD=0.15 
 
Intermediate  
precision 
Ruggedness 
%RSD  should not be  more  than  
2.0% 
The difference  between  assay  of  
method  precision and 
intermediate  precision should not  
be  more  than  2.0% 
Day  1 and  Analyst  1 
%  Assay  =99.68 
%  RSD    =0.43 
Day  2  and  Analyst  2 
%  Assay  =100.865 
%  RSD    =0.26 
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Accuracy 
Recovery  at  each  level  and  %  
mean  recovery  should  be  
between  100%   to  150%  with   
% RSD  should  not  be   more  
than  2.0% 
Recovery at  each  level 
98.55    to    101.88. 
Mean  Recovery 
99.86  to  101.78. 
%  RSD  = 0.18 
 
System suitability   
% RSD  should  not  be   more  
than  2.0% 
SD= 3.76352 
%RSD=0.18 
 
 
Robustness :             By change in flow rate 
 
 
 
a)0.9 ml/min 
 
 
b)1.1 ml/min 
 
 
 
%RSD  should  not  be  more 
than  2.0% 
Asymmetry factor  should  not 
be more than  2.0%. 
 
%RSD  should  not  be  more 
than 2.0%. 
Asymmetry  factor  should  not 
be  more  than  2.0% 
 
%RSD      = 0.019 
Asymmetry  factor  =1.105 
 
 
 
%RSD    =  0.21 
Asymmetry  factor  =1.161 
By change in wavelength 
a)248 nm 
 
 
 
 
b)244 nm  
% RSD should not be more than 
2.0% 
A symmetry factor should not be 
more than 2.0% 
 
% RSD should not be more than 
2.0% 
A symmetry factor should not be 
more than 2.0% 
% RSD =0.015 
Asymmetry factor = 1.114. 
 
 
 
% RSD =0.043 
Asymmetry factor = 1.167. 
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DISCUSSION: 
           The  observations and  results  obtained for  each  parameter  including  
Specificity,  Linearity  and  Range,  Precision   (System precision, Method  precision),  
Intermediate  precision  (Ruggedness),  Accuracy  and  Robustness  lie  well  within  
the  acceptance  criteria. 
 
CONCLUSION: 
        Since  the  results   are  with  in  acceptance  criteria  for  all  validation  
parameters, therefore,  the  method  is  considered  as  validated  and  suitable   for  
intended  use. 
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CONCLUSION 
For routine analytical purpose it is desirable to establish methods capable of 
analyzing huge number of samples in a short time period with good robustness, 
accuracy and precision without any prior separation step. HPLC method generates 
large amount of quality data, which serve as highly powerful and convenient 
analytical tool.  
Erlotinib was slightly soluble in methanol and very slightly soluble in water. 
Methanol and Mixture of Buffer was chosen as the mobile phase. The run time of the 
HPLC procedure was 10 minutes.  
The method was validated for system suitability, linearity, precision, accuracy, 
specificity, ruggedness robustness, LOD and LOQ. The system suitability parameters 
were within limit, hence it was concluded that the system was suitable to perform the 
assay. The method shows linearity between the concentration range of 10-60 µg / ml. 
The % recovery of Erlotinib was found to be in the range of 99.86 % - 101.78 %. As 
there was no interference due to excipients and mobile phase, the method was found 
to be specific. The method was robust and rugged as observed from insignificant 
variation in the results of analysis by changes in Flow rate and wave length separately 
and analysis being performed by different analysts.          
Good agreement was seen in the assay results of pharmaceutical formulation 
by developed method. Hence it can be concluded that the proposed method was a 
good approach for obtaining reliable results and found to be suitable for the routine 
analysis of Erlotinib in the pharmaceutical formulation.  
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